Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

5.415 -0.265 (-4.67%)
Streaming Delayed Price Updated: 3:51 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,333,445
Open 5.680
Bid (Size) 5.410 (10,100)
Ask (Size) 5.420 (5,200)
Prev. Close 5.680
Today's Range 5.330 - 5.915
52wk Range 1.865 - 9.750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale? ↗
This oncology biotech advancing targeted therapies reported a notable insider sale amid ongoing clinical-stage development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum ↗
Clinical-stage biotech Nuvation Bio, focused on oncology therapeutics, reported a recent insider buy amid a year of sharp share price gains. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
-36.9%
-36.9%
1 Month
+9.2%
+9.2%
3 Month
+26.2%
+26.2%
6 Month
-39.4%
-39.4%
1 Year
+177.7%
+177.7%

More News

Read More
News headline image
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗
Via The Motley Fool
Topics Regulatory Compliance
Nuvation Bio (NYSE:NUVB) Soars 22% After Earnings Beat Fueled by Strong Lung Cancer Drug Launch ↗
Via Chartmill
Topics Earnings
NUVATION BIO INC (NYSE:NUVB) Stock Plunges 9% After Q4 Earnings Reveal Revenue Beat but Wider Loss ↗
Via Chartmill
Nuvation Bio Stock Logs Its Best Session Ever: Wall Street Turns Bullish On Lung Cancer Drug’s Blockbuster Debut ↗
Via Stocktwits
News headline image
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Nuvation Bio (NUVB) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB) ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
From Pomerantz LLP
Via GlobeNewswire
News headline image
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
From Pomerantz LLP
Via GlobeNewswire
News headline image
SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold Conviction ↗
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy ↗
Via The Motley Fool
Topics Regulatory Compliance
Which stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
Nuvation Bio (NUVB) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
From Nuvation Bio and Eisai
Via Business Wire
News headline image
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio (NUVB) Soars on IBTROZI's Blockbuster Launch and Stellar Q3 2025 Performance
Via MarketMinute

Frequently Asked Questions

Is Nuvation Bio Inc. Class A Common Stock publicly traded?
Yes, Nuvation Bio Inc. Class A Common Stock is publicly traded.
What exchange does Nuvation Bio Inc. Class A Common Stock trade on?
Nuvation Bio Inc. Class A Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Nuvation Bio Inc. Class A Common Stock?
The ticker symbol for Nuvation Bio Inc. Class A Common Stock is NUVB on the New York Stock Exchange
What is the current price of Nuvation Bio Inc. Class A Common Stock?
The current price of Nuvation Bio Inc. Class A Common Stock is 5.415
When was Nuvation Bio Inc. Class A Common Stock last traded?
The last trade of Nuvation Bio Inc. Class A Common Stock was at 07/01/26 03:51 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.